Welcome to our dedicated page for NYSE news (Ticker: nyse), a resource for investors and traders seeking the latest updates and insights on NYSE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NYSE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NYSE's position in the market.
Actinium (NYSE: ATNM) announced that preclinical data for ATNM-400, a first-in-class Ac-225 antibody radioconjugate, will be presented at the 32nd Annual Prostate Cancer Foundation Scientific Retreat on October 23, 2025. The poster highlights durable anti-tumor activity in metastatic castration-resistant prostate cancer models, including activity in tumors resistant to enzalutamide and 177Lu-PSMA-617, and reports superior efficacy versus 225Ac-PSMA-617.
The release states ATNM-400 targets a distinct, non-PSMA antigen that is overexpressed after ARPI therapy, showed synergy with enzalutamide, and improved overall survival in preclinical models. The poster will be viewable online via the company investor relations page after the retreat.
Adient (NYSE) and Autoliv announced a co-developed safety solution for deeply reclined (zero-gravity) seating now ready for mass production. The system pairs Adient’s Z-Guard seating concept with Autoliv safety technologies to protect head, neck, chest and pelvis in reclined positions.
Key elements include an active cushion collapse mechanism, an adjustable seat belt outlet, integrated seatbelt system, dynamic lumbar retractor, pelvic cushion airbag and head side airbag. Z-Guard also supports predictive, high-speed seat repositioning via vehicle driver assistance integration and is scheduled for production in a high-volume model from a major global OEM.
Alexander & Baldwin (NYSE: ALEX) will report third quarter 2025 results after market close on Thursday, October 30, 2025. A conference call and webcast to discuss operating and financial performance is scheduled the same day at 5:00 p.m. ET.
Company participants include Lance Parker (president and CEO) and Clayton Chun (EVP, CFO and treasurer) with other senior management. Sell-side analysts may ask questions during the live call; webcast listeners will be in listen-only mode. Dial-in and webcast links and earnings documents will be available after market close on October 30, 2025.
Uber (NYSE:UBER) and Baidu (NASDAQ:BIDU) have announced a strategic multi-year partnership to deploy thousands of Baidu's Apollo Go autonomous vehicles on Uber's platform across global markets, excluding the US and mainland China.
The partnership will launch first in Asia and the Middle East in 2025, where riders requesting qualifying Uber trips may have their rides fulfilled by fully driverless Apollo Go vehicles. Apollo Go currently operates over 1,000 fully driverless vehicles across 15 cities, including Dubai and Abu Dhabi, and has completed more than 11 million cumulative rides.
Actinium Pharmaceuticals (NYSE: ATNM) has presented promising preclinical results for ATNM-400, a novel targeted radiotherapy for prostate cancer, at the AACR Annual Meeting. The data shows ATNM-400 outperforms Pluvicto, achieving 99.8% tumor growth inhibition with a single 40 µCi/kg dose.
Unlike Pluvicto and most prostate cancer radiotherapies that target PSMA, ATNM-400 is a first-in-class treatment targeting a distinct non-PSMA receptor that remains highly expressed even after Pluvicto treatment. The therapy utilizes Actinium-225, a more potent alpha-particle emitter than Lutetitium-177, causing irreversible DNA breaks with potentially fewer off-target effects.
Key findings demonstrate ATNM-400's efficacy in Pluvicto-resistant tumors, rapid internalization, sustained tumor uptake, and efficient clearance from essential organs. The treatment was well-tolerated with no apparent toxicities at both tested dose levels.
VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for April 9, 2025, at 10:00 AM ET, focusing on their Nu.Q® Cancer platform. Key executives including Chief Commercial Officer Gael Forterre, Chief Medical Officer Dr. Andrew Retter, and Chief Scientific Officer Dr. Jake Micallef will present.
The event will showcase findings from large independent studies supporting their Nu.Q® platform in cancer detection. Notably, recent research undergoing peer review indicates that the Nu.Q® Cancer test successfully detected multiple common cancers (lung, breast, prostate, colon, and liver) with an overall AUC of 86% and low false positive rates.
The company is targeting two significant market opportunities:
- The lung cancer market (screening, prognostication, and minimal residual disease) estimated at $4 billion
- The liquid biopsy market for multi-cancer early detection in the U.S., valued at approximately $20 billion
Actinium Pharmaceuticals (NYSE: ATNM) announced a business update presentation at Trump Mar-a-Lago Club, following their March 25th Investor KOL Event. The company highlighted three key clinical programs targeting multi-billion-dollar markets:
1. Actimab-A for myeloid malignancies and solid tumors:
- Phase 2/3 trial in combination with CLAG-M for AML
- Clinical trials for solid tumors with PD-1 inhibitors
2. Iomab-ACT for cell & gene therapy conditioning:
- Commercial CAR-T trial data from UT Southwestern
- Sickle cell disease trial data from Columbia University
3. Infrastructure Development:
- Manufacturing facility build-out starting next quarter
- Proprietary Actinium-225 cyclotron technology development
The company reports a strong balance sheet with runway into mid-2027, with multiple clinical milestones expected in 2025.
Actinium Pharmaceuticals (NYSE: ATNM) announces a KOL investor call highlighting three major market opportunities for their targeted radiotherapies. The call features Dr. Ehab Atallah from Medical College of Wisconsin discussing Actimab-A clinical results and upcoming trials.
The company is pursuing three distinct multi-billion-dollar opportunities:
- Actimab-A as a mutation agnostic, backbone therapy for myeloid malignancies
- Actimab-A combined with PD-1 inhibitors (KEYTRUDA and OPDIVO) for solid tumors
- Iomab-ACT as a universal targeted conditioning agent for cell & gene therapies
The presentation will cover clinical proof of concept data from frontline AML trial under NCI CRADA, the new Actimab-A solid tumor program with checkpoint inhibitors, and Iomab-ACT commercial CAR-T trial, along with other 2025 milestones.
Actinium Pharmaceuticals (NYSE: ATNM) has published results in the journal Leukemia for its Actimab-A + CLAG-M combination therapy trial in relapsed/refractory acute myeloid leukemia (r/r AML) patients. The trial demonstrated significant outcomes including:
- 18.4 months median Overall Survival in patients with 1-2 prior therapy lines
- 75% measurable residual disease negativity (MRD-) across all patients
- Strong efficacy in high-risk patients: 83.3% MRD- in TP53 mutation cases and 100% in prior Venetoclax therapy patients
- 71% of eligible patients received bone marrow transplant with 24.05 months median survival
The company plans to initiate a pivotal Phase 2/3 trial in 2025, comparing Actimab-A + CLAG-M versus CLAG-M alone in r/r AML patients. The treatment showed particular promise for high-risk patients, with results significantly exceeding historical survival rates of 2.4-4.6 months in Venetoclax-failed patients.